Avelumab in non-small-cell lung cancer
Mené sur 792 patients atteints d'un cancer du poumon non à petites cellules de stade avancé, cet essai de phase III compare l'efficacité, du point de vue de la survie gobale, et la toxicité de l'avélumab, un anticorps anti-PD-L1, et du docétaxel, en fonction du statut tumoral de PD-L1 et après un traitement à base de sels de platine
Antibodies targeting PD-1 (eg, nivolumab and pembrolizumab), or its ligand, PD-L1 (eg, atezolizumab), are approved as second-line therapy in non-small-cell lung cancer (NSCLC). The American Society of Clinical Oncology's 2017 Clinical Practice Guideline recommended pembrolizumab as second-line therapy in patients with NSCLC with PD-L1 tumour proportion scores of more than 1% (ie, patients with PD-L1 expression in 1% or more tumour cells). In the guideline, nivolumab and atezolizumab were also recommended as second-line therapy in patients with NSCLC with any level of PD-L1 expression. Other T-cell checkpoint inhibitors were not recommended in NSCLC.
The Lancet Oncology , commentaire, 2017